Annual reportSep 2026
Sep 2026 · Updates 1 Sep - 27th AGM on 26 September 2026; FY2025-26 annual report and notice shared.
Source: Nse
Par Drugs And Chemicals Limited (PAR)
Small CapIndustrials stocks · Small cap · NSE
Par Drugs And Chemicals Limited operates in Specialty Chemicals, within the Industrials sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers.
Data qualityFresh enough for analysisQuote updated 19 Oct, 03:51 pm ISTDetails
Quote19 Oct, 03:51 pm IST
Base fundamentals02 Oct 2026 · screener
Latest result16 Aug, 01:48 am IST
Score20 Oct, 04:30 am IST · v4.3-runtime-valuation
Tags02 May 2026
Coverage13/14 · 93%
Valuation2026-07-20 · Rf 6.8% · Industrials P/E 26.2 (n=537)
Technical timing lens
Trend score and candlestick chart
45NeutralSMA20 -5.3% / mo · MACD −
Stock trend: 42
Sector RS: 50
Sector 3M: -6.3% vs Nifty 500 -5.6%
Industrials FPI tailwindNot confirmed
Latest mapped FPI equity flow was not positive. View sector evidence
Technical chart
PARD candles · FIT view+16.0%Latest close ₹105.72 on 2026-10-19
Bar
-1.3%
RSI
33
MACD hist
-2.48
52W pos
27%
2026-10-19O ₹107.10H ₹109.00L ₹105.00C ₹105.72Vol 8,780 sh
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal
Market context
Relative performance and chart statistics
Adjusted completed-session prices, rebased to 100
PARNifty India ManufacturingNifty 500
- PAR
- +3.1%
- Nifty 500
- -5.6%
- Nifty India Manufacturing
- -5.8%
- Vs Nifty 500
- +8.6 pp
Chart stats
19 Oct 2026- From 52W high
- -41.3%
- 52W range position
- 27%
- ATR (14)
- 6.0%
- Volume vs 20D
- 0.75x
- Avg traded value
- ₹0.1 Cr
- 20D price channel
- ₹105 - ₹138
₹180
₹78.1 - ₹180
₹6.3
Latest completed session
20-session average
37.1% annualized volatility
Research snapshot
What the evidence says now
Weak fundamentals, management evidence is still limited to a financial-only Trust Lite signal, price trend is neutral, and recent execution is weak.
Suggested next step
Check latest quarters
Result consistency is weak; verify whether the thesis is improving or deteriorating.
U-Score
Legacy · WATCHLIST43
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Latest result
Excellent100
Revenue +20.1% · PAT +41.4% YoY
Technical
Neutral45
Price trend and sector-relative-strength timing.
Valuation
Legacy model-15.4%
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Trust
Limited evidence72
Financial-only signal; management claim evidence is not sufficient yet.
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Latest result
Quarter ended 30 Jun 2026
Excellent · 100/100Rev +20% YoY · PAT +41% YoY · margin expansion · +60% QoQ · operating leverage
Filed 30 Jun 2026
Open results browser →| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹31.3 Cr | +20.1% | +59.5% |
| EBITDA | ₹6.4 Cr | +78.9% | +342.4% |
| Operating margin | 20.4% | +669 bps | +1302 bps |
| PAT | ₹4.7 Cr | +41.4% | +454.1% |
| PAT margin | 15.1% | +228 bps | +1073 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Fundamentals
Valuation
- P/E
- 10.50
- P/B
- 1.36
- EV/EBITDA
- 6.38
- Market Cap
- 153.00Cr
Profitability
- ROE
- 9.95%
- ROCE
- 14.60%
- ROA
- 10.85%
- Dividend Y
- —
Growth (CAGR)
- Revenue 5Y
- 11.00%
- EPS 5Y
- 1.00%
- Revenue 3Y
- 3.00%
- EPS 3Y
- -2.00%
Balance Sheet
- Debt/Equity
- 0.00
- Interest Coverage
- —
- Altman Z
- 8.15
- Book Value
- 91.00
Cash Flow
- FCF Yield
- 9.15%
- FCF Positive Y
- 11/5
- OCF
- 16.00 Cr
- EPS TTM
- 11.78
Shareholding
- Promoter Hold
- 73.41%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 45%
Financial History
Updated 20/10/2026
Revenue
₹ CrLatest: 104+3.0% vs prev
Net Profit
₹ CrLatest: 13.0+0.0% vs prev
Return on Equity
%Latest: 11.6-11.6% vs prev
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Daily technical trend read
Bearish setupTrend is weak — long-term uptrend intact. RSI 33.
- Price above SMA200 (long-term uptrend) but mid-term MAs not aligned.
- SMA20 falling (~5.6% over last month) — short-term momentum negative.
- RSI(14) at 33 — falling, no extreme reading.
- MACD below signal but histogram contracting — bearish momentum easing.
- 41% off 52W high · 35% above 52W low.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Nifty 500 leadership
Relative Strength & Trend Stage
71
RS percentile
Stage 2 UptrendEstablished S2
1M return
-22.6%
3M return
+3.1%
6M return
+14.0%
1Y return
+4.9%
RS 1D
-1
RS 20D
-14
Sector rank
#2
Industry rank
#9
Stage evidence
- Price is 4.6% above the 30-week proxy.
- The 50-DMA is above the 30-week proxy and its slope is rising +4.2%.
- Both 3-month and 6-month returns are positive.
50-DMA
price below
200-DMA
price above
S2 entered
21 Aug 2026
S2 age
40 trading sessions
Sector
leading
Industry
leading
Relative-strength line vs Nifty 500 (base 100)
262 observations
19 Oct 2026Value 104.69-2.48%
RS vs Nifty 500105
Valuation & peers
U-Score 43 · legacy U-Score band WATCHLIST · valuation evidence and comparable companies
Valuation & peers
U-Score 43 · legacy U-Score band WATCHLIST · valuation evidence and comparable companies
WATCHLIST
Fundamental score breakdown
U band · WATCHLISTValuation20/30
Growth6/25
Quality1/20
Balance Sheet11/15
Cash Flow8/10
Piotroski
8/9 (+5)
Penalties
-8
Raw sum
43
Why this score?
Top U-Score contributors and drags from the latest stored fundamentals.
43/100 · legacy band WATCHLIST
Positive drivers
- FCF yield is supportive at 9.2%.
- Piotroski is strong at 8/9.
- Cash flow contributes 8/10 to the score.
Main drags
- Penalty bucket subtracts 8 points.
- Fair-value margin of safety is negative at -15.4%.
- Quality is weaker at 1/20; verify the latest quarterly trend.
Sector valuation model
Cyclical valuation: normalized earnings, not just trailing PE
Cyclical companies can look cheapest near peak profits, so IndiaPulse flags value-trap risk separately.
Primary lens
Mid-cycle PE/EV/EBITDA using multi-year average margins or earnings.
Secondary checks
Current margin versus 5-year average, balance sheet strength, commodity cycle.
Main risk check
A low trailing PE may mean peak-cycle earnings, not true cheapness.
PE
10.5
PB
1.4
EV/EBITDA
6.4
ROE
9.9%
ROCE
14.6%
FCF Yield
9.2%
Debt/Equity
0.0
MoS
-15.4%
Cyclical/value-trap warning
This sector can look cheap when profits are temporarily high. Check mid-cycle margins/earnings before relying on trailing PE.
Score movement
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Stored run: 20 Oct 2026
v4.3-runtime-valuation
Final score
43
Previous: 43
Legacy U-Score band
WATCHLIST
Previous: WATCHLIST
Margin of safety
-15.4%
Previous: -15.4%
Score history
12 stored score snapshots. Latest stored move: +0 points.
20 Oct 2026
v4.3-runtime-valuation
40
41
41
41
41
43
43
43
43
43
43
43
Factor attribution
No pillar movement versus the latest stored run. Historical score trend will appear after snapshot storage is enabled.
Modelled fair value
Graham Number
₹155.3
+29.5% MoS
Growth-justified P/E
8.1
Growth-justified Value
₹94.95
-15.4% MoS
PEG
10.50
Comparable companies
Peers
Business-comparable peers in Industrials — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Ticker
Name
Why peer
Score
PE
ROE
MoS
Verdict
KANCHI
Small
Kanchi Karpooram Limited
Specialty Chemicals
match 165
16
21.5
2.4%
-733%
OVERVALUED
HINDCON
Small
Hindcon Chemicals Limited
Specialty Chemicals
match 165
10
37.5
5.5%
-620%
OVERVALUED
HPIL
Small
Hindprakash Industries Limited
Specialty Chemicals
match 164
12
81.2
3.3%
-132%
OVERVALUED
ISHANCH
Small
Ishan Dyes and Chemicals Limited
Specialty Chemicals
match 163
6
—
-5.8%
—
OVERVALUED
ALKALI
Small
Alkali Metals Limited
Specialty Chemicals
match 162
25
34.3
1.3%
+16%
OVERVALUED
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business and thesis
Issuer presentation review pending
Par Drugs And Chemicals Limited operates in Specialty Chemicals, within the Industrials sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers. The structured result feed currently covers the quarter ended 30 Jun 2026. Investor presentations and earnings-call PDFs will be added as issuer-backed evidence before management claims appear here.
Trust Score
72Limited evidence · low confidenceTrust Lite
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Limited evidence: Claim history is still being built. It ranks around the 69th percentile of the scored universe and 67th percentile within Industrials. Main check: results consistency is weak at 31/100.
This is a financial-behaviour screen, not a claim-tested management reliability verdict.
Computed 05 Sept 2026
management-trust-v1
17 docs text-extracted · 0 concalls text-extracted
Score band
Limited evidence
Financial behaviour is scored, but management claims do not yet have enough outcome checks.
Relative rank
69th percentile
overall median 67 · Industrials: 67th pctile, median 68 · Small: 71st pctile, median 66
Evidence depth
Financial-only
17 documents have extracted text, but claim history is not strong enough yet.
Claim delivery
Outcome history still building
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Limited evidence · low confidenceWhat it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Acceptable, but check the weakest sub-score before increasing exposure.
Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Promoter
86
strong · holding, pledge, alignment
Cash flow
89
strong · profit to cash conversion
Balance sheet
88
strong · leverage and solvency
Discipline
50
watch · capital discipline
Results
31
weak · quarterly consistency
Trust positives
- ▸Promoter holding is 73.4%.
- ▸Promoter pledge is zero.
- ▸FCF yield is 11.1%.
- ▸11 years of positive FCF.
Trust risks
- ▸2 latest quarters had PAT decline worse than 25% YoY.
- ▸ROCE trend is -3.5%.
- ▸OPM spread across recent quarters is 26.2%.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Continue researching Par Drugs And Chemicals Limited
Important announcements & filings
Latest exchange and company disclosures found within the past two years.
Open source ↗
Annual report
Annual Report 2026
Source: Nse
Annual report
Annual Report 2025
Source: Nse
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.